# A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05816057` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05816057](<https://clinicaltrials.gov/study/NCT05816057>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05816057

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

## Technical summary

Registry record NCT05816057. Randomized; no masking; primary purpose treatment. Start 2022-07-25 (actual); primary completion 2023-07-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 476 participants (enrolled count; ClinicalTrials.gov record NCT05816057, source copy `cardio:ctgov-nct05816057-2024-01-03`, retrieved 2026-10-26)
- Started: 2022-07-25 (actual) (ClinicalTrials.gov record NCT05816057, source copy `cardio:ctgov-nct05816057-2024-01-03`, retrieved 2026-10-26)
- Primary completion: 2023-07-25 (actual) (ClinicalTrials.gov record NCT05816057, source copy `cardio:ctgov-nct05816057-2024-01-03`, retrieved 2026-10-26)
- Completion: 2023-10-31 (actual) (ClinicalTrials.gov record NCT05816057, source copy `cardio:ctgov-nct05816057-2024-01-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05816057, source copy `cardio:ctgov-nct05816057-2024-01-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05816057-2024-01-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Biological): semaglutide injection
- Lead sponsor: Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: c37c8e06b9ba2268617d7b2fc1d4ed256c41648cbfb0c63196786a532b6e26c4
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
